SomnoMed Limited’s shares are listed on the Australian Securities Exchange.
ASX announcements – Q1 2021 (July 2021 – Sept 2021)
ASX announcements – Q4 2020 (April 2020 – June 2020)
Appendix- 02A June 2020
S&P DJI Announces June 2020 Quarterly Rebalance
ASX Trading Update 2 June 2020
Q3 FY20 Results
Appendix 4C Q3 FY2020
Change of Director’s interest Notice
Change of Director’s interest Notice
Change of Director’s interest Notice
Change of Director’s interest Notice
Change in substantial holding
Appendix 2a
Results of Retail Entitlement offer
Change in substantial holding
Change of Director’s Interest Notice
Notification to ineligible shareholders
Retail Entitlement Offer Booklet
ASX announcements – Q3 2020 (January 2020 – March 2020)
Appendix 2a
Results of institutional Offer
Reinstatement to Official Quotation
Cleansing Notice – March 2020
Proposed issue of securities
Investor Presentation March 2020
Trading update and Entitlement offer
Investor Presentation
Half Year Accounts
Core revenue growth up 19% in Q2
Appendix 4C – quarterly
Suspension from Official Quotation
ASX announcements – Q2 2020 (October 2019 - December 2019)
ASX announcements – Q1 2020 (July 2019 - September 2019)
ASX announcements – Q4 2019 (April 2019 - June 2019)
ASX announcements – Q3 2019 (January 2019 - March 2019)
ASX announcements – Q2 2019 (October 2018 - December 2018)
ASX announcements – Q1 2019 (July 2018 - September 2018)
ASX Announcements – Q4 2018 (April 2018 - June 2018)
ASX Announcements – Q3 2018 (January 2018 – March 2018)
SOM Wilsons March 2018
Appendix 3Y Change of Director’s Interest Notice (RS) March 18
Appendix 3Y Change of Director’s Interest Notice (LA) March 18
TDM – Substantial Shareholder Notice 2018.03.22
Shareholding distribution – Analysis of Holdings as at 22-03-2018
SomnoMed – Appendix 3B 22.3.18 Retail Entitlements
Appendix 3Y Change of Director’s Interest Notice Feb 18
Announcement of Dispatch of Entitlement Offer – 26.2.18
SomnoMed – Appendix 3B 27.2.18 Institutional Entitlements
Confirmation of Release – SOM – Ceasing to be a substantial holder from AEF
SomnoMed – Announcement of Entitlement Offer 18.2.18 – Clean
Somnomed – Appendix 3B -19.2.18
SomnoMed – Cleansing Notice 18.2.18 – Clean
SomnoMed – Ineligible Shareholders Letter 18.2.18
Trading Halt – 19 February 2018
SomnoMed – Retail Entitlement Offer Booklet 20.2.18
SomnoMed – Results of Institutional Offer 20.02.18 – ASX Lodgement
SOM Feb 2018 Investors Presentation Final 18.02.18 ASX Lodgement
ASX Announcements – Q2 2018 (October 2017 – December 2017)
ASX Announcements – Q1 2018 (July 2017 – September 2017)
ASX Announcements – Q4 2017 (April 2017 – June 2017)
ASX Announcements – Q3 2017 (January 2017 – March 2017)
ASX Announcements – Q2 2017 (October 2016 – December 2016)
ASX Announcements – Q1 2017 (July 2016 – September 2016)
FDA 510k Approval for SomnoDent – 29.9.16
SomAppendix 3B 1.9.16
TDM SSH 26.8.16 – Form 604, Notice of change of interests of substantial holder
SomAppendix 3B 25.8.16
SOMApp3YPN 26.8.16
Form 605 Neustadt Shares 26.8.16
SomnoMed FY16 Presentation
SOM Preliminary Accounts FY16
Q4 ASX June 2016 Quarter Final
603 Initial Form SomnoMed Ltd – July 2016
SOM Appendix 4C – Quarterly Report for Entities Admitted on the Basis of Commitments
Derek Smith appointed Global CEO of SomnoMed
CEO appointed for new direct to patient business entity
ASX Announcements - Q4 2016 (April 2016 - June 2016)
Wilson HTM Equity Research – SOM – 1 June 2016
Appendix 03Y Change of Director’s Interest Notice June 2016
Appendix 03Y PN Change of Director’s Interest Notice June 2016
Appendix 03Y LA Change of Director’s Interest Notice June 2016
Results of Retail entitlement offer: 1 June 16
Shareholding Info 6.6.2016
Form 604- Notice of change of interests of substantial holder 6 June 2016
SomnoMed – Appendix 3B – 6 June 2016
SomnoMed – Appendix 3B – 13 May 2016
Announcement of Dispatch of Entitlement Offer – May 2016
SomnoMed – Results of Institutional Offer – FINAL May 2016
SomnoMed – Ineligible Shareholders Letter – May 2016
Announcement of Entitlement Offer – May 2016
Cleansing Notice – May 2016
SOM Investors Presentation FINAL May 2016
SOM Chair Letter May 2016
SOM- Appendix 3B – May 2016
SomnoMed – Ineligible Shareholders Letter – May 2016
SOM Appendix 3B – April 2016
ASX Announcements - Q3 2016 (January 2016 - March 2016)
ASX Announcements - Q2 2016 (October 2015 - December 2015)
FROST & SULLIVAN RECOGNISES SOMNOMED LIMITED AS OBSTRUCTIVE SLEEP APNEA COMPANY OF THE YEAR AT THE ANNUAL AUSTRALIAN EXCELLENCE AWARDS
Appendix 3YPN
AGM Results for ASX 2015
SOM Appendix 3B
SOM Appendix 3B6
SomnoMed acquires Strong Dental, Canada
SOM Appendix 3YLA
SOM Appendix 3YPN
SOM Appendix 3B
SomnoMed exceeds 250,000 patients
SomnoMed Proxy 2015
Notice of AGM of SomnoMed 2015
SOM Appendix 3B
GROWTH ACCELERATION IN THE US LEADS TO NEW RECORD QUARTER
ASX Announcements - Q1 2016 (July 2015 - September 2015)
ASX Announcements - Q4 2015 (April 2015 - June 2015)
ASX Announcements - Q3 2015 (January 2015 - March 2015)
Continuous Growth of SomnoMed in Third Quarter
Appendix 4C Quarterly (Q3)
Ceasing to be a substantial shareholder
Addition of SomnoMed to Australian All Ordinaries Index
Ceasing to be a substantial shareholder
Appendix 3B New issue announcement
Appendix 4D and Half-Year Financial Review
Investor Presentation: Financial Year 2014-2015 Half Year Review
SomnoMed Achieves Growth Targets
Appendix 3B New Issue Announcement January 2015
Appendix 4C Quarterly
ASX Announcements - Q2 2015 (October 2014 - December 2014)
Form 604 TDM Asset Management December 2014
Appendix 3B New Issue Announcement December 2014
Appendix 3YRS December 2014 – Change of Director’s Interest Notice
Appendix 3YLA – Change of Director’s Interest Notice
Appendix 3YPN – Change of Director’s Interest Notice
Appendix 3YRS – Change of Director’s Interest Notice
Form 604 Belgove December 2014
Appendix 3B New Issue Announcement: application for quotation of additional securities and agreement
Annual Meeting Minutes
SOM Shareholder Change Form Form 604
SomnoMed Exceeds 200,000 Patients
ASX Investor Presentation November 2014
SomnoMed Limited (SOM) Q1 Stock Analysis, Morgans CIMB
SomnoMed Limited (SOM) Q1 Stock Analysis, Wilson HTM
Notice of Annual General Meeting
SomnoMed Limited Proxy Form
Appendix 3B – New issue announcement,application for quotation of additional securities and agreement
New Records in September Confirm Guidance (ASX:SOM)
Appendix 4C – Quarterly report for entities admitted on the basis of commitments
ASX Announcements - Q1 2015 (July 2014 - September 2014)
US Medicare reimbursement approval granted for SOMNODENT® Herbst Advance
Appendix 3B New issue announcement
SOM:ASX 2014 SHARE PURCHASE PLAN – CLOSES OVERSUBSCRIBED
SomnoMed (”SOM”-ASX) Preliminary final report – 30 June 2014
SOM – Investor Presentation FY14
Appendix 3YLA – Change of Director’s Interest Notice
Appendix 3Y – Change of Director’s Interest Notice
SOM – Change in Substantial Holding
SomnoMed (”SOM”-ASX) Share Placement Update
SomnoMed SOM 708A Cleansing
SomnoMed Limited Appendix 3B – New Issue Announcement
SomnoMed (SOM) Research
SomnoMed Italy
ASX Announcements - Q4 2014 (April 2014 - June 2014)
ASX Announcements – Q3 2014 (January 2014-March 2014)
ASX Announcements – Q2 2014 (October 2013-December 2013)
Appendix 3B_New Issue Announcement
Appendix 3B_New Issue announcement
Appendix 3Y_Change of Director’s Interest
Appendix 4C_Quarterly Report
C
ontinuing Global Growth for SomnoMed
Exclusive Agreement Signed for Compliance Measurement
SomnoMed Acquired 2nd Largest OA Company in France
SomnoMed General Meeting_Nov12
ASX Announcements – Q1 2014 (July 2013-September 2013)
Every State in the United States of America, and most countries throughout the world have their own laws regulating the types of securities and other investment products which maybe offered to their residents, as well as the process for doing so. As a result, investment in some securities is not available to every interested investor. Accordingly, this information is provided for informational purposes only, and does not constitute an offer or solicitation to buy or sell Somnomed Limited shares in any jurisdiction where such would be prohibited.
All investments involve different degrees of risk. In making any investment you should be aware of your risk tolerance level and financial situations at all times. Furthermore, you should seek professional investment advice before making any investment decisions. Somnomed Limited and/or its shareholders, directors, officers and/or employees make no investment recommendations in respect to any investment made in Somnomed Limited.
